ArticleFrontiers in neurology2026
Assessing efgartigimod dosing patterns and Myasthenia Gravis Activities of Daily Living outcomes in clinical practice: results from a large patient support program database.
Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Practical Guidance on Initiating and Switching Targeted Immunotherapies in Generalised Myasthenia Gravis: A German-Austrian Expert Opinion Paper.European journal of neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Efgartigimod, a neonatal Fc receptor (FcRn) blocker, is approved for the treatment of generalized myasthenia gravis (gMG). Evidence describing large-scale cohorts in routine United States (US) practice remains limited. Objective: To characterize efgartigimod dosing patterns and Myasthenia Gravis Activities of Daily Living (MG-ADL) outcomes among a US cohort enrolled in the My VYVGART Path patient support program. Methods: This retrospective cohort study analyzed adults with gMG who initiated efgartigimod on or before December 31, 2025, and had a baseline (pre-efgartigimod) MG-ADL score recorded and ≥4 follow-up assessments available. Outcomes included dosing interval distributions, longitudinal MG-ADL trends, durability of clinically meaningful improvement (CMI; ≥2-point reduction), and best observed response. Results: Among 3,326 eligible patients (mean [SD] baseline MG-ADL: 8.2 [3.8]; mean [SD] treatment duration: 18.0 [11.0] months), the most common inter-cycle interval length was 4 weeks, though intervals ranged widely, reflecting individualized care. Patients achieved rapid and sustained clinical improvement, with mean MG-ADL improvement of 3.3 points by Month 1 and 4.5 points by Month 18. Of 2,964 patients achieving CMI, the majority (>75%) maintained CMI for >80% of their available follow-up time. Best observed response analyses showed a mean (SD) improvement from baseline of 5.9 (3.5) points, with 83% achieving MG-ADL score ≤4 and 47% achieving minimal symptom expression (MG-ADL score 0-1). Conclusion: In this large and diverse US cohort, efgartigimod was administered using both proactive (structured) and individualized (flexible) dosing strategies, leading to rapid, deep, and sustained clinically meaningful improvements. These findings support efgartigimod as an effective and adaptable therapy for gMG in routine clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.